Snowden Capital Advisors LLC
Position in MDGL — Madrigal Pharmaceuticals, Inc.
CIK 1903055
New York, NY
Position in MDGL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,247,429
-$48,277 QoQ
Shares Held
2,383
+7.1% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Snowden Capital Advisors LLC holds $12,608,129 across 22 Biotechnology names. MDGL ranks #4 (9.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,864 | $2,212,840 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,833 | $1,711,587 | |
| 3 | ARGX |
Argenx SE
|
2,117 | $1,545,939 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
This page
|
2,383 | $1,247,429 | |
| 5 | INSM |
INSMED Inc
|
7,571 | $1,238,009 | |
| 6 | MRNA |
Moderna, Inc.
|
12,722 | $646,277 | |
| 7 | IDYA |
IDEAYA Biosciences, Inc.
|
19,231 | $640,776 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
1,197 | $355,473 |
All Filings in MDGL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,247,429 | 2,383 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,295,706 | 2,225 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,151,236 | 2,510 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $640,991 | 2,118 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $706,182 | 2,132 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $587,825 | 1,905 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $326,606 | 1,539 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $409,593 | 1,462 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||